No Password Required: From Heavy Metal to the Front Lines of Cyber Innovation
Daily Compliance News: August 20, 2025, The Boss is Back Edition
Daily Compliance News: August 19, 2025, The AI Winter Edition
10 For 10: Top Compliance Stories For the Week Ending August 16, 2025
AI Today in 5: August 15, 2025, The AI as Boss Episode
The LathamTECH Podcast — Turning a London Eye Toward International Tech Growth
Daily Compliance News: August 14, 2025 The End of Dial Up Edition
Daily Compliance News: August 13, 2025. The Bad App Store Ratings Edition
Episode 381 -- Cadence Design Pays $140 Million to Settle Trade Violations
AI Today in 5: August 7, 2025. The US v. China Episode
LathamTECH in Focus: Move Fast, Stay Compliant
Daily Compliance News: August 6, 2025, The Spanking Banks Edition
Daily Compliance News: August 1, 2025, The All AI Edition
Daily Compliance News: July 30, 2025, The Corruption Kill Business Edition
Innovation in Compliance: Scaling Compliance Programs: Insights from a Navy Veteran and Compliance Leader
Daily Compliance News: July 28, 2025, The Where is Grasshopper when you need him Edition
JONES DAY TALKS®: Real Assets Roundup Episode 2: A First Look at Data Centers: The Fourth Utility
LathamTECH in Focus: Tech Deals: The Emerging Focus of FDI Regulators?
LathamTECH in Focus: Navigating National Security: The Impact of FDI Reviews on Tech M&A
Compliance Tip of the Day: Rethinking Corporate AI Governance Through Design Intelligence
Cooley handled 238 reported venture capital financings in Q2 2025, representing $6.5 billion of invested capital. Deal count increased by more than 20% across all stages of financing compared to the previous quarter, with...more
Wilson Sonsini's 2024 Technology and Life Sciences PIPE and RDO Report provides an analysis of 205 private investments in public equity (PIPEs) and registered direct offerings (RDOs) by U.S.-based technology and life sciences...more
Wilson Sonsini's 2024 Technology and Life Sciences IPO Report provides in-depth analysis on 33 initial public offerings (IPOs) completed by U.S.-based technology and life sciences companies in 2024 with deal values exceeding...more
Key Takeaways from October Deal activity: The final quarter of 2024 did not get off to a strong start in October, but dealmakers remain optimistic that the dealmaking environment will continue to improve and transaction...more
The 2023 Technology and Life Sciences PIPE and RDO Report presents analysis related to 177 private investments in public equity (PIPEs) and registered direct offerings (RDOs) by U.S.-based technology and life sciences...more
Meanwhile, cash-strapped biotechs have in many cases been forced to leverage relationships with big pharma to address liquidity. Cash is king in a financing environment such as we have observed over the last 18 months, and...more
In this issue of the 2022 Technology and Life Sciences IPO Report, we present analysis related to 10 initial public offerings (IPOs), valued at over $75 million, completed by U.S.-based technology and life sciences companies...more
In this inaugural issue of the 2022 Technology and Life Sciences PIPE Report, we present analysis related to 108 private investments in public equity (PIPEs) by U.S.-based technology and life sciences companies between...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q1 2023 include: • Life sciences VC deal value totaled $5.0 billion across 364 deals, representing a 40.9% decline in value...more
Competition regulators across the world have traditionally perceived non-horizontal mergers as less likely to be problematic because there is substantive scope for efficiencies....more
Our survey analyzed the terms of 287 venture financings closed in the fourth quarter of 2021 by companies headquartered in Silicon Valley. Key Findings - • Valuation results again reached new record highs, with the...more
Corporate governance practices vary significantly among public companies. This is a reflection of many factors, including: • Differences in the stage of development of companies, including the relative importance placed on...more
Despite political and economic uncertainties, markets and deal activity were resilient in 2019, and strong fundamentals remain in place heading into 2020. Companies continue to face a challenging litigation and enforcement...more
This report analyzes key aspects of initial public offerings (IPOs) for technology and life sciences companies that went public in 2016. Our IPO Survey was developed for clients, friends and others interested in considering...more
Our 2016 IPO Report offers a detailed analysis of, and outlook for, the IPO market, plus useful IPO market metrics. We look at rates of adoption of JOBS Act relief by emerging growth companies, and recent FAST Act amendments...more
The 2015 IPO market produced 152 IPOs, a disappointing tally that lagged well behind the 244 IPOs in 2014 despite continued strength in the life sciences sector. Setting aside the anomalous years of 2008 and 2009, however,...more